Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mantle cell lymphoma
Pharma
BeOne’s Brukinsa hits goal in lymphoma confirmatory trial
Overall survival data will likely be key in BeOne’s approval bid, given Imbruvica’s earlier U.S. withdrawal in MCL.
Angus Liu
Jun 30, 2026 6:00am
BeOne's Venclexta challenger Beqalzi nets FDA approval
May 13, 2026 4:45pm
FDA OKs BMS' Breyanzi as first CAR-T for marginal zone lymphoma
Dec 5, 2025 11:00am
Trial results show value of Lilly's Jaypirca in front-line CLL
Sep 8, 2025 11:37am
AZ makes case for Calquence in another blood cancer type
Jun 17, 2024 11:25am
AZ clinches early Calquence win in untreated MCL
May 2, 2024 10:24am
